Journal of Clinical Lipidology
Volume 4, Issue 2 , Pages 133-135 , March 2010

A case report of a diabetic woman with very low HDL cholesterol

  • Leila Chaychi, MD

      Affiliations

    • Department of Endocrinology and Metabolism, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756-0001, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • William B. Kinlaw, MD

      Affiliations

    • Department of Endocrinology and Metabolism, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756-0001, USA
    • ,
  • Bela F. Asztalos, PhD

      Affiliations

    • Lipid Metabolism Laboratory, Tufts University, Boston, MA, USA
    • ,
  • Ernest J. Schaefer, MD

      Affiliations

    • Lipid Metabolism Laboratory, Tufts University, Boston, MA, USA

Received 26 October 2009 ,Accepted 21 January 2010.

References 

  1. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
  2. Brunzell JD. Hyper Triglyceredimia clinical practice. N Engl J Med. 2007;357:1009–1017
  3. Asztalos BF, Collins D, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25:2185–2191
  4. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008;62:1959–1970
  5. Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review). J Nutr Biochem. 2003;14:298–305
  6. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544–1568
  7. Goldenberg I, Boyko V, Tennenbaum A, Tanne D, Behar S, Guetta V. Long-term benefit of high-density lipoprotein cholesterol–raising therapy with Bezafibrate, 16-year mortality follow-up of the Bezafibrate Infarction Prevention Trial. Arch Intern Med. 2009;169:508–514
  8. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science. 2004;305(5685):869–872
  9. Pearson JR, Dusenbury LJ, Bakes-Martin R, Loverde M, Johnson J, Byyny RL. Evaluation of a simple method for measuring blood cholesterol levels using non- laboratory observers. Am J Med. 1988;85:369–374
  10. Miller M, Zhan M. Genetic determinants of low high density lipoprotein cholesterol. Curr Opin Cardiol. 2004;19:380–384
  11. Rust S, Rosier M, Funke H, Real J, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22:3168
  12. Miller M, Rhyne J, Hamlette S. Genetics of HDL regulation in humans. Curr Opin Lipidol. 2003;14:273–279
  13. Rhyne J, Mantaring MM, Gardner DF, Miller M. Multiple splice defects in ABCA1 cause low HDL-C in a family with hypoalphalipoproteinemia and premature coronary disease. BMC Med Genet. 2009;10:1
  14. Zambon A, Brown BG, Deeb SS, Brunzell JD. Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease. J Intern Med. 2006;259:473–480
  15. Asztalos BF, Roheim PS, Milani RL, et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:2670–2676
  16. Clee SM, Kastelein JJ, van Dam M, et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest. 2000;106:1263–1270

PII: S1933-2874(10)00042-5

doi: 10.1016/j.jacl.2010.01.003

Journal of Clinical Lipidology
Volume 4, Issue 2 , Pages 133-135 , March 2010

Article Tools

* Image Usage & Resolution